Multiple nurses working on the same floor of busy hospital develop brain tumors
At least five nurses working on the same floor of a Boston-area hospital have been diagnosed with brain tumors, and they're looking for answers.
The nurse's union at the hospital, the Massachusetts Nurses Association (MNA), told Fox News Digital in a statement that it is actively supporting nurses at Newton-Wellesley Hospital in Newton, "who have brought forward serious medical concerns, focused on brain tumor diagnoses on the 5th floor maternity unit."
"We recognize that nurses and many other people want immediate information about the situation," the MNA continued. "This urgency comes from a place of concern for the health of nurses, their families, and patients — an urgency that we share."
The MNA further said it is working to "complete an independent, scientific investigation" into the diagnoses.
"That effort is underway and may take additional weeks," the MNA said. "The investigation is being conducted by the MNA's division of health and safety, consisting of occupational health nurses, in collaboration with the Newton-Wellesley nurses."
In addition, the nurses' union said it has received more than 300 survey responses, emails and phone calls from current and former nurses, as well as other current and former hospital employees, regarding their health concerns.
Newton-Wellesely reportedly conducted its own exam in December and found that through April, 11 staff members who worked, at some point and to varying degrees, on the fifth floor of the hospital, had been interviewed by the hospital's Occupational Health and Safety (OHS), according to a memo obtained by Boston.com.
The hospital determined that five cases were benign brain tumors of three different types, and six cases were determined not to be brain tumors at all but other health concerns, according to the memo.
The investigation further "found no environmental risks which could be linked to the development of a brain tumor," Jonathan Sonis, associate chief medical officer, and Sandy Muse, chief nursing officer, said in a statement to Boston.com.
"Based on these results, we can confidently reassure our dedicated team members at Mass General Brigham/Newton-Wellesley Hospital and all our patients that there is no environmental risk at our facility," the statement continued. "As always, the health and wellbeing of our staff, clinicians, and patients is our absolute top priority."
The OHS review did find that there were 668 X-rays performed with portable machines on the fifth floor of Newton-Wellesley between 2020 and 2024, doubling the risk of radiation exposure compared to normal daily radiation exposure for nurses standing approximately one meter from the machine, according to Boston.com.
"Even if a staff member had been present for all of these X-rays, however, they would not have absorbed this much exposure (i.e., one meter from the machine) as we utilize appropriate X-ray safety techniques throughout the hospital," the memo obtained by the outlet states.
Newton-Wellesley did not immediately respond to an inquiry from Fox News Digital.
The MNA said it is working with the hospital, which it says "only spoke to a small number of nurses and their environmental testing was not comprehensive."
"The hospital cannot make this issue go away by attempting to provide a predetermined conclusion," the MNA added. "While we currently cannot release specific numbers or other diagnosis information, we are committed to being transparent about our findings when we have finished verifying the information we collect.
"Completing this step-by-step process is critical to providing the support Newton-Wellesley nurses deserve."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
6 hours ago
- Bloomberg
Harvard AIDS Research, Affiliated Hospitals Hit by Trump Feud
The Trump administration's funding battle with Harvard University is starting to impact projects at affiliated hospitals and has crippled the school's Center for AIDS Research, one of the largest backers in the US for emerging studies on the condition. Harvard funnels a portion of its federal grants to research partners, including the Mass General Brigham hospital system, and that money has now largely stopped flowing after the government froze more than $2.6 billion in support. Mass General researchers whose work is affected should 'stop all activity and spending' unless they have found alternative funding, Paul Anderson, the hospital group's chief academic officer, said in a message to staff late last week.
Yahoo
7 hours ago
- Yahoo
NY state Senate approves doctor-assisted suicide bill, sends it to Hochul's desk for approval
ALBANY – State Senate Democrats passed highly controversial legislation that would allow terminally ill people to take their own lives with the help of doctors in a razor-thin vote Monday — leaving it up to Gov. Kathy Hochul whether to sign it into law. 'This is one of the great social reforms of our state,' state Sen. Brad Hoylman-Sigal (D-Manhattan), the bill's sponsor in the upper chamber, touted at a press conference earlier in the day Monday — putting the measure on the same tier as the legalization of gay marriage. 'This is about personal autonomy, this is about liberty, this is about exercising one's own freedom to control one's body,' Hoylman-Sigal continued. The measure passed 35 to 27, with six Democrats – Senators April Baskin, Siela Bynoe, Cordelle Cleare, Monica Martinez, Roxanne Persaud, and Sam Sutton – voting against it. 'The governor will review the legislation,' a spokesperson for Hochul said. The bill's passage follows a years-long campaign that was fought tooth and nail by a diverse group of critics, including disability rights activists and the Catholic church, as well as many black and Orthodox Jewish communities. 'The Governor still has the opportunity to uphold New York's commitment to suicide prevention, protect vulnerable communities, and affirm that every life—regardless of disability, age, or diagnosis—is worthy of care, dignity, and protection,' The New York Alliance Against Assisted Suicide wrote in a statement following the vote. A Catholic group slammed the bill's passing as 'a dark day for New York' and also called on Hochul to refuse to sign it. 'For the first time in its history, New York is on the verge of authorizing doctors to help their patients commit suicide. Make no mistake – this is only the beginning, and the only person standing between New York and the assisted suicide nightmare unfolding in Canada is Governor Hochul,' Dennis Poust, Executive Director of the New York State Catholic Conference, wrote in a statement. Ahead of the vote, the nearly three-hour debate on the Senate floor got emotional, with several lawmakers holding back tears as they explained their votes. Syracuse-area state Sen. Rachel May (D-Onondaga) shared the story of her late husband, who was receiving morphine in the final stages of his battle with cancer, which he eventually succumbed to at 32 years old. 'I don't know if the last largest dose he took also took his life, but I know that he died in peace,' May said. 'It isn't about controlling the disease or controlling the pain, it's about having control at the end of your life,' she said before voting in favor. Critics fear the legislation lacks critical safeguards over how doctors approve patients looking to receive the prescription for a lethal cocktail of drugs, such as a statutory waiting period, establishing clear chain of custody for the pills, mandating the doctor and recipient meet in-person, and requiring a disclosure that someone indeed used the drugs to take their own life. Under the bill, recipients would need approval from two doctors and a sign-off from two independent witnesses, after which they would receive a prescription for drugs they could use to take their life at a time of their choosing. Doctors also do not have to conduct a mental health screening for each patient, but may refer a patient for one under the legislation. 'I don't think requesting end-of-life medication when an individual is suffering and in pain and dying suggests a mental health condition, if anything, I think it's quite rational,' Hoylman-Sigal said. Hoylman vowed the bill would not lead to such 'unintended consequences.' 'It was a professional organization that provided us crucial guidance, that helped us develop the state-of-the-art safeguards in this legislation that gave my colleagues and the general public, I believe, the assurance that there will not be unintended consequences,' he said. The legislation is referred to by its supporters as the 'Medical Aid in Dying' bill. 'The option of medical aid in dying provides comfort, allowing those who are dying to live their time more fully and peacefully until the end. I am profoundly grateful to Senate Majority Leader Stewart-Cousins for giving her conference the space to have this important and emotional discussion,' Corinne Carey, Senior Campaign Director of Compassion and Choices, the main group driving the effort to pass the bill, wrote in a statement.
Yahoo
11 hours ago
- Yahoo
Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria
ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study BOSTON and LAUSANNE, Switzerland, June 10, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany's Paul-Ehrlich-Institut (PEI) to initiate a Phase 1/1b study of ALY-301 in healthy volunteers and patients suffering from Cold Urticaria, a subtype of Chronic Inducible Urticaria (CIndU). Cold Urticaria is a chronic skin disease where red, itchy wheals or hives appear after the skin is exposed to cold temperatures. It is a well-established clinical model for mast cell-mediated diseases in general, and chronic spontaneous urticaria in particular. Current and emerging solutions do not address the significant unmet medical needs experienced by patients. In conjunction with limited treatment options, the Urticaria market is projected to reach multiple billions within the next ten years. ALY-301 is the first mast cell-selective c-Kit inhibitor to enter the clinic. It is a cis-targeting bispecific antibody binding c-Kit and CD-203c, allowing selective targeting and depletion of mast cells over other c-Kit positive cells. This differentiated profile of ALY-301 is expected to offer a significantly improved safety profile over conventional c-Kit targeting agents and enable safe, chronic dosing in multiple mast-cell dependent diseases such as Chronic Urticaria. The trial will evaluate the safety and efficacy of ALY-301 at multiple sites across Germany. This CTA submission is the first clinical program to emerge from Alys' Granular platform, which is focused on the precise targeting of mast cell biology through advanced antibody engineering. Professor Brian Kim, Sol and Clara Kest Professor of Dermatology and Vice Chair of Research at Icahn School of Medicine at Mount Sinai and Head of Alys Pharmaceuticals Scientific Advisory Board, said: "ALY-301 offers a truly differentiated approach. It is the only c-Kit antibody designed to target activated mast cells while avoiding off-target effects. Unleashing the proven efficacy of c-Kit inhibition on mast cells, while sparing all other cell-types that have been associated with significant side effects, should result in a transformational drug profile for ALY-301 and could have a revolutionary impact on Chronic Urticaria and several other allergic indications." Professor Martin Metz, Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin & Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology and Principal Investigator for ALY-301, commented: "The concept behind ALY-301, to enable safe and effective chronic dosing of a c-Kit agent through mast-cell selectivity, has been strongly supported across all non-clinical studies. It is very exciting to start the clinical journey today, especially since this first clinical trial will yield clinical outcomes from Urticaria patients." Thibaud Portal, Co-Founder and Chief Operating Officer of Alys Pharmaceuticals, added: "Recently, there has been intense attention to solving Urticaria and other allergic diseases, with keen interest in c-Kit targeting. Data have demonstrated the remarkable potency of the mode of action, but indiscriminate c-Kit targeting has been coupled with chronic safety challenges. ALY-301 is a first-in-class approach that combines the power of c-Kit inhibition with selectivity and safety. With its expected safety margin and broad applicability across multiple diseases, this marks another pivotal moment for Alys in our journey to bring innovative treatments to patients." This study marks the second major clinical milestone for Alys Pharmaceuticals. The Alys pipeline includes a diverse portfolio of assets targeting unmet needs in indications such as atopic dermatitis, chronic spontaneous urticaria, vitiligo, and systemic mastocytosis. The Company remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027. About Alys PharmaceuticalsAlys Pharmaceuticals, Inc. ("Alys") is a Boston and Lausanne-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder, and COO Thibaud Portal. Its pipeline includes programs targeting multiple dermatological indications, including atopic dermatitis, vitiligo, chronic urticaria, psoriasis and mastocytosis. The Company entered the clinic in Q1 2025 with the siRNA platform developed by its affiliate Aldena Therapeutics, which offers the potential for long-lasting treatments that could transform the dermatology treatment landscape and is now advancing its mastocyte-selective therapies developed by affiliate Granular Therapeutics. For further information, please visit View original content: SOURCE Alys Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
